Company intelligence / Profile preview

Hunan Changde Sanjin Pharmaceutical

Ownership: Private
Development stage: Phase 2

Overview

The company manufactures a broad range of proprietary traditional Chinese medicines with over-the-counter approval status. Its affiliate network has entered clinical development of monoclonal antibodies through external partnerships. For example, the herbal formula "Yuye Jiedu Granule" has demonstrated concerted inhibition of mTORC1/2 and NF-kappaB pathways in preclinical studies.

Therapeutic areas: OtherPulmonologyOncologyInfectious Diseases
Modalities: Herbal medicineSmall moleculeMonoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

yuye jiedu granules

Unknown

Partnerships

Adagene for monoclonal antibodies developmentpossible internal supply chain links to Dragonboat Biopharmaceutical

Beyond the preview

Go deeper on Hunan Changde Sanjin Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hunan Changde Sanjin Pharmaceutical.

Explore the full profile